High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease

Serena Bugatti; Antonio Manzo; Barbara Vitolo; Francesca Benaglio; Elisa Binda; Martina Scarabelli; Frances Humby; Roberto Caporali; Costantino Pitzalis; Carlomaurizio Montecucco

doi:10.1093/rheumatology/keu163

High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease

Serena Bugatti, Antonio Manzo, Barbara Vitolo, Francesca Benaglio, Elisa Binda, Martina Scarabelli, Frances Humby, Roberto Caporali, Costantino Pitzalis, Carlomaurizio Montecucco

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13 levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte activation and joint damage. Results. In patients with early disease (

Original language	English
Pages (from-to)	1886-1895
Number of pages	10
Journal	Rheumatology
Volume	53
Issue number	10
DOIs	https://doi.org/10.1093/rheumatology/keu163
Publication status	Published - Oct 1 2014

Keywords

B lymphocytes
Biomarkers
CXCL13
Rheumatoid arthritis
Synovium

ASJC Scopus subject areas

Rheumatology
Pharmacology (medical)

Access to Document

10.1093/rheumatology/keu163

Cite this

@article{c0c772a9cffc4c17917bb221240df468,

title = "High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease",

abstract = "Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13 levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte activation and joint damage. Results. In patients with early disease (",

keywords = "B lymphocytes, Biomarkers, CXCL13, Rheumatoid arthritis, Synovium",

author = "Serena Bugatti and Antonio Manzo and Barbara Vitolo and Francesca Benaglio and Elisa Binda and Martina Scarabelli and Frances Humby and Roberto Caporali and Costantino Pitzalis and Carlomaurizio Montecucco",

year = "2014",

month = oct,

day = "1",

doi = "10.1093/rheumatology/keu163",

language = "English",

volume = "53",

pages = "1886--1895",

journal = "Rheumatology",

issn = "1462-0324",

publisher = ". Published by Oxford University Press on behalf of the British Society for Rheumatology",

number = "10",

}

TY - JOUR

T1 - High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease

AU - Bugatti, Serena

AU - Manzo, Antonio

AU - Vitolo, Barbara

AU - Benaglio, Francesca

AU - Binda, Elisa

AU - Scarabelli, Martina

AU - Humby, Frances

AU - Caporali, Roberto

AU - Pitzalis, Costantino

AU - Montecucco, Carlomaurizio

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13 levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte activation and joint damage. Results. In patients with early disease (

AB - Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13 levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte activation and joint damage. Results. In patients with early disease (

KW - B lymphocytes

KW - Biomarkers

KW - CXCL13

KW - Rheumatoid arthritis

KW - Synovium

UR - http://www.scopus.com/inward/record.url?scp=84900001764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900001764&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keu163

DO - 10.1093/rheumatology/keu163

M3 - Article

C2 - 24764267

AN - SCOPUS:84900001764

VL - 53

SP - 1886

EP - 1895

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 10

ER -

High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this